• Ahmed M Alkhunaizi, Hanaa Abd Elnabi, Abdulrazack Amir, and Amber Anwar.
• From the Department of Medicine, Specialty Internal Medicine Division, Nephrology Unit (Alkhunaizi, Amir, Anwar), and from the Department of Nursing (Abd Elnabi), Johns Hopkins Aramco Healthcare, Dhahran, Kingdom of Saudi Arabia.
• Saudi Med J. 2022 Jun 1; 43 (6): 633-636.

ObjectivesTo report the outcome of patients with end stage kidney disease (ESKD) who were diagnosed with COVID-19 at a large community hospital in Eastern Saudi Arabia.MethodsA single center, prospective observational study at Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia. Patients with ESKD who were maintained on dialysis and developed COVID-19 between June 15, 2020 and October 31, 2021 were enrolled.ResultsIn total, 30 patients with ESKD were diagnosed with severe acute respiratory syndrome coronavirus 2 infection. Twenty two (73%) patients developed the disease prior to COVID-19 vaccine rollout. The median age of the cohort was 63 (55-75) years. Most patients were diabetic (73%), hypertensive (97%) and had a median body mass index of 28 kg/m2. Twenty seven (90%) patients required admission, 16 (52%) patients developed pneumonia, and 5 (17%) patients required mechanical ventilation. Patients who developed pneumonia were older, and the majority had diabetes mellitus and coronary artery disease. Five patients died with a total mortality of 17%.ConclusionPatients with ESKD who developed COVID-19 had a poor outcome with high mortality compared to the general population. Presence of diabetes mellitus, coronary artery disease and older age were associated with a higher risk of severe disease. There was a sharp decline in the number of positive cases following implementation of the vaccination program.Copyright: © Saudi Medical Journal.

20 keywords...

hide…